Latest filings (excl ownership)
15-12G
Securities registration termination
22 Jun 09
8-K
Bankruptcy or Receivership
22 Jun 09
8-K
Other Events
16 Jun 09
10-Q
2009 Q1
Quarterly report
12 Jun 09
10-K
2008 FY
Annual report
2 Jun 09
8-K
Other Events
20 May 09
S-8 POS
Registration of securities for employees (post-effective amendment)
19 May 09
S-8 POS
Registration of securities for employees (post-effective amendment)
19 May 09
S-8 POS
Registration of securities for employees (post-effective amendment)
19 May 09
S-8 POS
Registration of securities for employees (post-effective amendment)
19 May 09
NT 10-Q
Notice of late quarterly filing
18 May 09
8-K
Other Events
20 Apr 09
8-K
Departure of Directors or Certain Officers
1 Apr 09
NT 10-K
Notice of late annual filing
1 Apr 09
8-K
Other Events
27 Mar 09
25-NSE
Exchange delisting
26 Mar 09
8-K
Other Events
23 Mar 09
8-K
Entry into a Material Definitive Agreement
18 Mar 09
8-K
Other Events
20 Feb 09
8-K
Atherogenics Provides Update on Bankruptcy Proceedings
22 Jan 09
8-K
Other Events
21 Jan 09
8-K
Other Events
22 Dec 08
8-K
Departure of Directors or Principal Officers
10 Dec 08
8-K
Other Events
3 Dec 08
10-Q
2008 Q3
Quarterly report
17 Nov 08
8-K
AtheroGenics Reports Third Quarter 2008 Financial Results
12 Nov 08
NT 10-Q
Notice of late quarterly filing
12 Nov 08
8-K
AtheroGenics Receives Delisting Notice from NASDAQ Global Market Due to Chapter 11 Filing
10 Oct 08
RW
Registration withdrawal request
10 Oct 08
8-K
Bankruptcy or Receivership
7 Oct 08
8-K
Cost Associated with Exit or Disposal Activities
23 Sep 08
8-K
Departure of Directors or Principal Officers
18 Sep 08
8-K
Other Events
16 Sep 08
8-K
Departure of Directors or Principal Officers
11 Sep 08
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation under an Off-Balance Sheet Arrangement
2 Sep 08
CT ORDER
Confidential treatment order
25 Aug 08
10-Q
2008 Q2
Quarterly report
11 Aug 08
8-K
AtheroGenics Reports Second Quarter 2008 Financial Results
5 Aug 08
8-K
AtheroGenics Reports Positive Results from ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
31 Jul 08
8-K
AtheroGenics Receives Notice of Non-Compliance with Listing Requirement for the NASDAQ Global Market
30 Jun 08
Latest ownership filings
No filings